Clinical Trials Logo

Osteosarcoma Metastatic clinical trials

View clinical trials related to Osteosarcoma Metastatic.

Filter by:
  • None
  • Page 1

NCT ID: NCT04803877 Active, not recruiting - Osteosarcoma Clinical Trials

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Start date: June 4, 2021
Phase: Phase 2
Study type: Interventional

A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.

NCT ID: NCT04651179 Completed - Clinical trials for Osteosarcoma Recurrent

Study of Effectiveness of GEMDOX in Relapsed Osteosarcoma

Start date: April 24, 2020
Phase:
Study type: Observational

A retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with HD IFO in first line treatment

NCT ID: NCT04546243 Completed - Pulmonary Disease Clinical Trials

Osteosarcoma With Resectable Pulmonary Metastasis: A Retrospective Study

Start date: January 1, 2020
Phase:
Study type: Observational

According to EURAMOS-1, 17% of osteosarcoma patients were considered to have metastases at diagnosis. In this selected cohort, the reported 5-year EFS from diagnosis of 28% compares well to previous results reported from unselected cohorts of patients with only lung metastases. Resection of pulmonary metastases from osteosarcoma is a treatment option which has been shown to correlate with survival benefit and cure in select individuals. These patients are best addressed in a multidisciplinary fashion, with the involvement of a thoracic surgeon with experience in pulmonary metastasectomy. At the same time, the goal of surgical resection of pulmonary metastases from osteosarcoma is to render the patient completely disease free. "Tumor debulking" or "cytoreductive surgery" with incomplete resection has not demonstrated any survival benefit for patients with pulmonary metastases. Thus open thoracotomy is more preferred than VATS. However over the last decade in China, thoracotomy has not been adopted generally. More patients had chosen VATS or even hypo-fractionation radiotherapy, such as gamma knife, cyber knife and so on as a local treatment method. This study aims to investigate the survival of consecutive patients who had achieved a first complete surgical remission (CR) during combined-modality therapy on neoadjuvant or adjuvant PKUPH-OS protocol so as to discuss reasonable local therapy for resectable pulmonary osteosarcoma metastatic lesions.

NCT ID: NCT04183062 Active, not recruiting - Clinical trials for Osteosarcoma Metastatic

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Start date: October 4, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study of an investigational drug, BIO-11006, for the treatment of lung metastases in pediatric patients with advanced osteosarcoma or Ewing's sarcoma. This study will enroll up to 10 patients aged between 5 and 21 at Nicklaus Children's Hospital in Miami, FL. Patients will receive BIO-11006 in addition to chemotherapy consisting of gemcitabine and docetaxel. This study will test the hypothesis that BIO-11006 will enhance the effect of the gemcitabine and docetaxel chemotherapy to treat lung metastases in osteosarcoma and Ewing's sarcoma.